warrant premium pt rais
room
model assum abbv franchis gener
board meet feb leav plenti dri powder humira
exceed immunolog heme/onc pipelin posit
lessen depend rais pipelin sale ep
 street trade discount group averag
deserv premium sales/ ep cagr
vs street reiter buy/rais pt
ep
strong cf oper execut rais pt
strong oper execut across best-in-class immunolog oncolog
hcv franchis creat strong engin free cash flow expect
gener provid tremend
financi flexibl immunolog humira matur expect abbv
next-gener asset upadacitinib/risankizumab build leadership
positon hematolog imbruvica/venclexta best-in-class asset posit
pivot solid tumor rova-t hcv presenc mavyret
 emerg women health franchis elagolix pdufa
rais sales/ep street
sales/ep cagr vs street
best group see meaning upsid abbv share sinc
trade ep turn discount group averag
model assum rais dividend announc
share buy-back program board meet februari
reiter buy rais pt assum trade
ep support dcf risk includ clinic regulatori
triniti risankizumab upadacitinib lt data file
humira lower concentration/less burn formul us well
humira growth support vs abbv
humira growth simpli impress brand size global
 late life-cycle year market key
tr target
geographi humira broad label earli entri penetr grow inflamm market
segment patient year therapi dtc invest result high degre sticki
physician patient even face new brand uniqu mechan action
 indirect biosimilar competit also believ street underestim durabl
humira growth due competit next-gener asset ii humira loss exclus
next-gener immunolog drug il/jak-inhibitor pois challeng humira howev
under-penetr biolog class mean immunolog remain fertil ground humira
growth believ under-penetr biolog one key reason overal
immunolog market us grow see exhibit despit intens competit humira
robust volume-driven growth high-singl expect tribut brand high
market share across approv use humira market share bulk label indic
despit entri next-gener asset see exhibit indirect biosimilar competit
abbv humira ip-litig rate settl click note
potenti trial boehring ingelheim bi privat sever year away click note
think near-term risk earli humira loe us low date commerci effort
brand manufactur maintain volum share meant indirect biosimilar see
slow uptak ex-u market particularli us final share humira citrate-
free/low volum formul avail us initi pediatr patient
give year switch meaning portion us humira user new formul prior
biosimilar entri earli alreadi switch ex-u volum new
formul think switch less painful/low concentr humira formul could make
franchis durabl allow franchis continu outperform street expect
rais humira sale prior vs street
model abbv immunolog sale grow vs street
humira matur abbv next-gener asset upadacitinib upad oral
inhibitor risankizumab risa intraven subcutan inhibitor posit
extend compani leadership global immunolog market global immunolog market
model assum market grow present
major data upad risa risankizumab shown unpreced efficaci
four psoriasi phase trial result superior humira click note
track submit global regulatori file risa launch assum
us psoriasi pso market risa label expans crohn diseas cd
underway ulcer coliti uc initi later psoriat arthriti trial
underway add leg growth rais risa sale estim prior vs
street abbv main next-gener immunolog pipelin asset upadacitinib
demonstr robust efficaci profil rheumatoid arthriti ra three six plan phase
trial click note expect upad data three ra trial select-
compar select-earli select-choic aim submit nda file base
result six trial upad also clinic develop cd
uc atop dermat ad readi remind upad top-lin result ad
impress view click look in-depth analysi present
full data aad meet feb rais upad sale prior vs
street overal believ humira durabl combin strong uptak risa
 upad help maintain leadership posit immunolog humira loe
well-posit heme/onc vs biopharma
well posit oncolog market-lead asset hematolog hem along
promis solid tumor platform oncolog stemcentrx acquisit click
event without market io asset think better posit sever
major pharma player high growth oncolog market expect top
click imbruvica venclexta cement abbv leadership posit
hem/onc market view expect grow
imbruvica broad label leadership chronic lymphocyt leukemia cll market
share cll comprehens clinic develop program establish cornerston
asset portfolio also bullish imbruvica combo potenti phase readout
expect cll combin gazyva dlbcl combin r-chop
venclexta unpreced murano data click note posit approval/
page
launch relapsed/refractori cll expect venclexta grow tap untreat section
r/r cll without materi cannib imbruvica share indic base regulatori
feedback also acceler venclexta phase trial acut myeloid leukemia aml two
year revis plan file anticip approv begin
model imbruvica/venclexta sale vs street solid tumor
franchis remain cautious optimist rova-t registrationaltrin studi
small cell lung cancer sclc expect read-out opin previous
click believ rova-t may gain first-mov advantag high unmet medic
need area sclc note trial carri high degre clinic risk even
triniti success rova-t initi uptak like focus later line therapi
expect rova-t face competit bristol-my buy opdivo yervoy combo
earli line therapi seek expans rova-t earlier line therapi
taho studi sclc meru studi sclc well expans neuroendocrin
tumor type basket studi total commerci opportun rova-t across
indic peak-year sale estim howev modestli model sale
vs street believ risk associ slow start rova-t mitig
solid tumor asset current early-stag clinic trial also plan advanc
sever asset human trial
believ mavyret good exampl kind innov commerci execut
becom known sinc spin abbott rate mavyret
value-bas price discount combin pan-genotyp efficaci shorter durat therapi
help enabl signific uptak surpris mavyret achiev market
leadership market launch month launch mavyret alreadi
command share us hcv market accord weekli data mavyret uniqu clinic
profil help secur pariti access hcv regimen cover live
us expect mostli stabl price volum us market modest
single-digit potenti downward pressur volum gain manag care
access past two month expect mavyret perform de-risk abbv goal global
hcv sale target model abbv total hcv sale vs
street project
balanc sheet strength pursu ambit
multipl franchis deliv strong growth support robust pipelin opportun abbv
next growth frontier expect could come busi develop call
identifi oncolog neurosci compani focu term inorgan growth said
correct opportun aris plenti dri powder ambit bolt-on entir
new therapeut area near-term view partner logic tuck-in note
previous click exist partnership
rate elagolix focus neurosci women two
therapi area want grow acquisit long-term also
look opportun drive growth time-frame model assum gener
free cash flow could use support compani
goal without sacrif grow dividend model growth vs
 step-up annual share repurchas model vs
 alreadi strong improv balanc
sheet model net debt/ebitda fall comment
call compani expect repurchas debt take dollar valu long-term debt
rapidli debt matur suggest think could take net debt/ebitda
high right transact peak pharmacycl acquisit
support assumpt purs acquisit multipl deal without
pipelin catalyst place upward pressur abbv multipl
bounti catalyst drive out-perform su astrazeneca azn
rate infring three btk-inhibitor relat patent imbruvica district court
delawar case next catalyst litig schedul confer jan
roll outth humira lower volum citrate-fre formul pediatr patient
page
us mavyret launch trajectori trx/sale figur import metric
look build-out imbruvica label includ interim phase result mantl
cell lymphoma shine follicular lymphoma selen expect venclexta r/r
cll approv base phase data expect upadacitinib data
three rheumatoid arthriti trial select-compar select-earli select-
choic throughout aim submit nda file drug base result six
trial full result upadacitinib phase trial atop dermat expect
present american academi dermatolog aad san diego feb
track submit risankizumab psoriasi result fda support launch
us catalyst includ elagolix data uterin fibroid fda action elagolix
endometriosi earli prioriti review rova-t top-lin data triniti
sclc full data like june two ptab decis whether institut ipr
two humira patent exhibit detail catalyst calendar
page
page
product rang rang rang midpoint strh estimatesconsensu total growth usnot growth ex-usnot peak sale assum biosimilar entri globalnot usnot viekira mavyret globalnot viekira mavyret us growth weight base approv r/r clllupron provid flat providedless provid flat provid flat incom totalnot provid approach marginnot sale sale provid marginnot expensenot ratenot rate rise next year rate lower due one-tim benefitnet incomenot providednot providednot increas octob oper rest tax epsnot outstand dilut providednot providednot indic rang updat impli us ex-u rang abbvi inc
page
millionscurrentcurr chg chg total non-oper expens incom dilut ep analysiscurrentcurr chg chg bp gross changecurrentcurr chg chg bp total millionscurrentcurr chg chg total non-oper expens incom dilut ep analysiscurrentcurr chg chg bp gross changecurrentcurr chg chg bp total inc
exhibit estim strh vs consensu
page
exhibit us immunolog market year-over-year yoy growth rate jan oct
exhibit humira market share first-lin indic us market jan oct
page
exhibit pipelin strh vs consensu
page
exhibit in-lin product strh vs consensu
page
page
datecompanyproductev categoryev sub-typecommentjan aznimbruvicalegallitigationa rule schedul teleconfer set btk inhibitorsfeb data releasepres full result atop dermat data aad meet san diego data releasephas elagolix data uterin nvshumiralegalptab actiondecis whether institut sandoz ipr humira patent formul patent data releas cll/sll ibr gv nvshumiralegalptab actiondecis whether institut sandoz ipr humira patent method use patentearli actionanticip approv elagolix endometriosi prioriti data releasesclc triniti data base sclc pso base result immvent data releasephoenix phase ibr-rchop possibl submiss dlbcl combo w/ rchop data data cll imb gazyva vs chl gazyva data ra select-compar data data full data r/r fl vs br trial atop derm studi expect begin data full data dlbcl rchop vs rchop mabclin trial milestoneiniti evid biolog activ multipl file acut myeloid leukemia aml patient receiv high-dos induct data releaseuc phase biosimilarregulatoryema actionema action expect adalimumab biosimilar file accept trial uc studi expect begin data basket studi neuroendocrin tumor data avail bmyrova-t/ opdivo yervoyclin data releasestart see data rova-t combin opdivo/ trial initiationiniti phase trial ulcer data ra select-earli data abbvi inc
page
datecompanyproductev categoryev upadacitinib data r/r fl/mzl combo w/ br r-chop data data releas uterin data releas resolv data releasephas solid tumor data releas immerg r/r mm ibr actionregulatori approv expect base r/r cll murano broader label actionregulatori approv expect aml patient receiv high-dos induct launch expect sclc assetsclinicalind ind novel target trial initiationnsclc start pivot nsclc trial initiationnsclc start nsclc w/ data releas intellance-j data releas vela nsclc actionfil pso base result immvent data releasefin data releas uterin submiss uterin data releasedata phase trial multipl myeloma data releas immpact data releas alliance-ctep data releasephas cll data releasephas data releas velia phase approv uterin data releasethre phase trial risankizumab crohn data cll gi data releas alliance-ctep cllnov trial uterin fibroid abbvi inc
page
 incom net ep ep outstand analysisgross changetot metricspric inc
page
asset -- -- -- -- -- -- -- -- -- -- -- -- -- invest tax -- -- -- -- -- -- -- -- -- -- -- prepaid current properti intang non-curr liabil short-term payabl accru matur lt current liabilitieslong-term long-term non-curr equiti additon paid stock comprehens incom compani invest -- -- -- -- -- -- -- -- -- -- -- -- -- total liabil abbvi inc
exhibit statement flow
page
flow oper activ net incom compens in-process asset liabil account cash use oper flow invest activ purchas properti invest net cash restrict fund -- -- -- -- -- -- -- -- -- -- -- -- -- sale purchas product right net -- -- -- -- -- -- -- -- -- -- -- -- -- decreas increas restrict cash increas market secur cash use invest flow financ activ proce repay short-term issuanc long-term long-term debt common stock option transact abbott laboratori -- -- -- -- -- -- -- -- -- -- -- -- -- dividend cash flow provid financ fx cash cash increas decreas cash cash cash equival begin cash equival end abbvi inc
inc highli focus research-driven biopharmaceut compani discov
develop deliv innov therapi treat health issu rang life-threaten ill
chronic condit gener total net sale sale deriv
us intern market compani core area expertis immunolog
hematology/oncolog virolog neurosci gener medicin
humira largest pharmaceut product histori biopharmaceut industri
total revenu come differ indic abbv second largest franchis hematology/
oncolog imbruvica/venclexta franchis account sale abbv
virolog franchis includ hepat product viekira/mavyret account
sale
rate buy favorit valu name large-cap biopharmaceut sinc
launch believ time humira loss exclus us along
pipelin underappreci street thesi base humira us exclus
allow extract maximum valu franchis asset diversifi
revenu stream hematology/oncolog immunolog pipelin humira ideal
posit us volum driven growth price leverag well margin expans associ
expir upper single-digit royalti sale think evolv legal
regulatori landscap suggest us humira biosimilar competit delay januari
due long date humira patent estat global immunolog market model assum biosimilar
competit ex-u market late us earli legal catalyst around humira
play expect street push biosimilar entri us toward earli estim
put upward pressur street consensu humira sale estim
pipelin ideal posit view extern collabor intern
deriv asset provid next gener therapi autoimmun disord improv upon
humira best class profil posit leverag global humira infrastructur
pipelin immunolog asset includ upadacitinib select oral inhibitor risankizumab
monoclon antibodi target also posit reduc humira biosimilar risk
maxim hematology/oncolog franchis includ imbruvica venclexta hematolog
malign rova-t solid tumor model sales/ep cagr vs
valuat risk
price target assum trade ep premium major
biopharmaceut peer group expect abbv trade premium group settl
us patent disput humira pipelin matur multipl data read out immunolog
hematolog oncolog asset play model assum humira total sale account
sale immunolog hematology/oncolog sale new product
label expans exist asset rise sale
risk valuat includ earlier expect humira biosimilar competit us
market addit assum compani abl gener revenu pipelin
lower humira total revenu clinic regulatori commerci
setback key pipelin asset upadacitinib risankizumab imbruvica venclexta rova-t elagolix
etc could forc look extern acceler diversif sale prior humira loss
exclus us invest risk relat pharmaceut industri gener includ
continu price risk payer especi europ polit risk product develop risk
regulatori risk commerci risk legal risk patent challeng
compani mention note
abbott rate
amgen inc rate
page
astrazeneca plc azn rate
inc rate
john bori herebi certifi view express research report accur reflect
person view subject compani secur also certifi
receiv direct indirect compens exchang express specif
recommend report
